Back to All Events

Peripheral and Central Nervous System Drugs Committee

On Thursday, April 19, 2018 the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted, by a vote of 13-Yes to 0-No, with no abstentions that the benefit-risk profile of Epidiolex (cannabidiol oral solution), by GW Pharmaceuticals (GW), is favorable for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years of age and older.